Cinacalcet: Use Criteria
Real-time data for Patient Management
The BC Provincial Renal Agency provides funding for cinacalcet (Sensipar®) on a restricted basis to individuals who fail conventional therapy or who meet the criteria as described on the application form to be completed by the nephrologist.
There are currently no outcome studies with evidence that lowering PTH is of benefit with respect to morbidity and mortality. Due to some individual data that suggests that severe symptomatology may be benefited by lowering the PTH level (but not so low as to induce low bone turnover disease), the BCPRA Pharmacy Formulary Review Committee made the decision to fund on a restricted basis.
Nephrologists who would like to put a patient on cinacalcet (Sensipar®) are asked to submit the application form to BCPRA. An adjudication team of three Pharmacy Formulary Review Committee members will review each request, with approval given on a case-by-case basis. Due to costs, the use of this drug will be closely monitored. The funding policy will be re-evaluated periodically.Documents
BCPRA is not responsible for any misuse of the posted documents.
If you have any questions about the documents, please contact the BCPRA at 604-875-7340 or by email